Life Sciences

Life Sciences

Filter all offers by subject

OsteoProtect - Treatment of osteoporosis by inhibitors of sphingosine-1phosphatase (S1P)-lyase

pdf

Ref.-No. 4955

There are currently 200 million people suffering from osteoporosis worldwide. Low bone mass and deteriorating bone quality lead to an increased risk of fractures, high morbidity and increased mortality. According to the International Osteoporosis Foundation, one in three women and one in five men over the age of 50 will experience osteoporotic fractures. Current pharmacological therapy consists of antiresorptive agents, none of which stimulates new bone formation.

Keywords: Osteoporose, Sphingosin-1-Phosphatase (S1P)-Lyase-Inhibitoren, Neuartige Therapie für Knochenschwund, Osteoporosis, inhibitors of sphingosine-1-phophatase (S1P)-lyase, novel therapy for bone loss

Bone tissue undergoes dynamical remodeling by the coordinated action of bonedegrading osteoclasts and bone-forming osteoblasts. 
 
The inventors showed that S1P inhibited osteoclast function, but most importantly, stimulated osteoblasts to produce new bone. Thus, a sufficient S1P-concentration is fundamental for an osteoanabolic fine-tuning of the skelettal system.
 
Furthermore they showed that high S1P counteracts obesity by reducing adipose tissue mass.
 
According to the invention, in patients suffering from osteoporosis, bone formation may be facilitated (and obesity reduced) by administering inhibitors of the S1P-lyase (the key enzyme degrading S1P). An exemplary S1P-lyase inhibitor tested by the inventors is the compound 4deoxypyridoxin (DOP). The compound showed clear therapeutic potential in mouse models of genetic and hormonal (estrogen deficiency) osteoporosis. Another compound might be LX2931.  S1P blood concentration was also an indicator of bone health in a study with over 4000 human individuals.

Competitve Advantages

  • Novel approach for treating reduced bone density/stability
  • Specific inhibitors identified
  • In vivo data available

Commercial Opportunities

The invention is offered for licensing.
 
Current Status

In vivo data are available (see publication below). A patent application has been filed.
 
Relevant Publication

Weske, S. et al. (2018): Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss. Nat. Med. 24(5): 667-678.
 
An invention of the University of Duisburg-Essen.


Please contact me about this offer

Dr. Constanze Vogel
+49.208 94105-41
cv@provendis.info

Dr. Constanze Vogel

This offer

Contact

PROvendis GmbH · Schloßstr. 11 – 15
D – 45468 Mülheim an der Ruhr
T +49 (0)208 94105-0 · kontakt@provendis.info